This is an interesting case report that shows that the combination therapy of oral vancomycin and ustekinumab (Stelara) put a 25-year old PSC-UC patient into remission with her ulcerative colitis.

Ultimately, the authors conclude that, in patients with ulcerative colitis, oral vancomycin may change the microbiome in a way that improves dysbiosis and reduces inflammation in the colon. They go on to say that PSC-IBD patients who don’t respond to standard therapy may want to consider oral vancomycin in possible combination with biologic therapy.

Get the details below!